International Scientific Program Committee
David A. Wink
EDUCATION/TRAINING
Institution Degree Year Field
State University of New York College at Oneonta B.S. 1980 Chemistry
University of California, Santa Barbara Ph.D. 1985 Inorganic Chemistry
Massachusetts Institute of Technology Postdoctoral Fellow 1985-9 Bioinorganic Chemistry








POSITIONS HELD:
1989-1992 Staff Fellow, Chemistry Section, Laboratory of Comparative Carcinogenesis National Cancer Institute, NIH, Frederick, MD
1992-1995 Senior Staff Fellow, Chemistry Section,Laboratory of Comparative Carcinogenesis, National Cancer Institute, NIH, Frederick, MD
1995-1999 Senior Staff Fellow, Radiation Biology Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD
1999-present Senior Investigator/Section Chief, Radiation Biology Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD

HONORS AND OTHER SCIENTIFIC RECOGNITION (Selected):
2008 Fellow, American Association for the Advancement of Science
Federal Technology Transfer Award
2009 Chair, Gordon Conference, “Nitric Oxide”
Federal Technology Transfer Award
Faculty Member, Faculty of 1000
2013 Member of the Electorate Nominating Committee (ENC)
American Association for the Advancement of Science



BIBLIOGRAPHY
Citations: 17,034; h index of 69, average citation 53.57 (as of 5/2012 ISI)
(20 out of 260)
  1. Andrei D, Salmon DJ, Donzelli S, Wahab A, Klose JR, Citro ML, Saavedra JE, Wink DA, Miranda KM, Keefer LK. Dual mechanisms of HNO generation by a nitroxyl prodrug of the diazeniumdiolate (NONOate) class. J Am Chem Soc. 2010 Nov 24;132(46):16526-32.
  2. Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, Goodman JE, Yfantis HG, Lee DH, Ambs S. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010 Nov 15;10:626.
  3. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L, Haskó G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010 Dec 14;56(25):2115-25.
  4. Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011 Jun;89(6):873-91.
  5. Flores-Santana W, Salmon DJ, Donzelli S, Switzer CH, Basudhar D, Ridnour L, Cheng R, Glynn SA, Paolocci N, Fukuto JM, Miranda KM, Wink DA. The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. Antioxid Redox Signal. 2011 May 1;14(9):1659-74.
  6. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, Pagliaro P, Gao WD, van Eyk J, Kass DA, Wink DA, Paolocci N. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011 May 1;14(9):1687-98.
  7. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011 Jun 2;30(22):2504-13.
  8. Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011 May 15;50(10):1368-81.
  9. Flores-Santana W, Moody T, Chen W, Gorczynski MJ, Shoman ME, Velázquez C, Thetford A, Mitchell JB, Cherukuri MK, King SB, Wink DA. Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells. Br J Pharmacol. 2012 Feb;165(4b):1058-67.
  10. Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, Wink DA. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011 Nov;32(11):644-51.
  11. Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA. Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation. 2011 Sep 9;8:115.
  12. Fukuto JM, Carrington SJ, Tantillo DJ, Harrison JG, Ignarro LJ, Freeman BA, Chen A, Wink DA. Small molecule signaling agents: the integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. Chem Res Toxicol. 2012 Apr 16;25(4):769-93.
  13. Horváth B, Mukhopadhyay P, Kechrid M, Patel V, Tanchian G, Wink DA, Gertsch J, Pacher P. β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med. 2012 Apr 15;52(8):1325-33.
  14. Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen RT Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. J Pharmacol Exp Ther. 2012 Jun;341(3):873-81.
  15. Switzer CH, Cheng RY, Ridnour LA, Murray MC, Tazzari V, Sparatore A, Del Soldato P, Hines HB, Glynn SA, Ambs S, Wink DA. Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer. Cancer Res. 2012 May 1;72(9):2394-404.
  16. Schoenfeld MP, Ansari RR, Nakao A, Wink D. A hypothesis on biological protection from space radiation through the use of new therapeutic gases as medical counter measures. Med Gas Res. 2012 Apr 4;2:8.
  17. Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res 10(9):1203-15, 2012.
  18. Gao WD, Murray CI, Tian Y, Zhong X, Dumond JF, Shen X, Stanley BA, Foster DB, Wink DA, King SB, Van Eyk JE, Paolocci N Nitroxyl(HNO)-Mediated Disulfide Bond Formation Between Cardiac Myofilament Cysteines Enhances Contractile Function. Circ Res. 111(8):1002-11, 2012. (Editorial on the article Ge and Moss Circ. Res. 2012, 111, 954-956.
  19. Sohn JJ, Schetter AJ, Yfantis HG, Ridnour LA, Horikawa I, Khan MA, Robles AI, Hussain SP, Goto A, Bowman ED, Hofseth LJ, Bartkova J, Bartek J, Wogan GN, Wink DA, Harris CC. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS ONE, 7(9):e44156, 2012.
  20. Ridnour LA, Barasch KE, Windhausen AN, Dorsey TM, Yfantis HG, Lee DH, Switzer CH, Glynn SG, Cheng RYS, Ambs S, Wink DA. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS ONE, 7(9):e44081, 2012.
  21. Soto-Pantoja DR, Rinour LA, DeGraff W, Wink DA, and Roberts DD. Blockade of CD47 increases survival and protects tissue of mice exposed to total body irradiation. Sci Rep. 2013;3:1038. doi: 10.1038/srep01038. Epub 2013 Jan 8.
PATENTS
  1. Keefer LK, Wink DA, Dunams TM, Hrabie JA. Stabilized nitric oxide-primary amine complexes useful as cardiovascular agents. U.S. Patent 4,954,526, September 4, 1990.
  2. Keefer LK, Wink DA, Dunams TM, Hrabie JA. Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof. U.S. Patent 5,039,705, August 13, 1991.
  3. Keefer LK, Wink DA, Dunams TM, Hrabie JA. Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof. U.S. Patent 5,208,233, May 4, 1993 (continuation in part of U.S. Patent 5,039,705).
  4. Keefer LK, Wink DA, Dunams TM, Hrabie JA. Antihypertensive compositions and use thereof. U.S. Patent 5,212,204, May 18, 1993.
  5. Christodoulou D, Wink DA, Keefer LK. Mixed ligand metal complexes of nitric oxide nucleophile adducts useful as cardiovascular agents. U.S. Patent Application 07/858,885, March 27, 1994.
  6. Malinski T, Wink DA, Younathan J, Murray RW, Sullivan M, Meyer TJ, Christodoulou DD. Nitric oxide specific electrode. U.S. Patent Application 07/918,661, filed July 22, 1992. U.S. Patent Application 5,603,820, February 18, 1997.
  7. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE, Cook JA. Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers, filed October 8, 1993. U.S. Patent Application 5,650,442, July 22, 1997.
  8. Wink DA, Mitchell JB, Russo A, Krishna MC, Hanbauer I. Use of nitric oxide releasing compounds to treat ischemia reperfusion injury, filed September 12, 1995. U.S. patent 5,789,447, August 4, 1998.
  9. Keefer LK, Wink DA, Dunams TM, Hrabie JA. Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof. U.S. Patent 5,731,305, March 24, 1998 (continuation in part of U.S. Patent 5,039,705 and a division of Pat No. 5,208,233).
  10. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE, Cook JA. Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers, filed October 8, 1993. U.S. Patent No. 5,814,667, September 19, 1998.
  11. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE, Cook JA. Use of nitric oxide releasing compounds to sensitize cancerous cells to chemotherapeutic agents, filed March 11, 1997. U.S. Patent No. 5,837,736, November 17, 1998.
  12. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE, Cook JA Use of nitric oxide releasing compounds to protect non-cancerous cells from chemotherapeutic agents, filed October 8, 1993. U.S. Patent No. 5,840,759, November 24, 1998.
  13. Wink DA, Kass DA, Paolocci N, Feelisch M, Miranda KM, Fukuto LM. The Role of Nitroxyl (HNO) Progenitors in Treatment of Heart Failure. Filed, May, 2002 U.S. Patent No. 6,936,639 B2, August 30, 2005.